Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Journal of Clinical Pathology

• Publication date

  1987-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1136/jcp.40.4.404PMID 3584483PMCID PMC1140972
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dose response studies using desferrioxamine and orally active chelators in a mouse model.

  2009cited by this paper
• Iron mobilization from ferritin using α-oxohydroxy heteroaromatic chelators

  1986cited by this paper
• The study of iron mobilisation from transferrin using alpha-ketohydroxy heteroaromatic chelators.

  1986cited by this paper
• Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits.

  1986cited by this paper
• The study of iron mobilisation from transferrin using α-ketohydroxy heteroaromatic chelators

  1986cited by this paper
• Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.

  1986cited by this paper
• Iron mobilization from ferritin using alpha-oxohydroxy heteroaromatic chelators.

  1986cited by this paper
• Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

  1985cited by this paper
• New orally active iron chelators.

  1985cited by this paper
• Orphan drugs and orphan diseases: clinical realities and public policy. Proceedings of a conference, Ann Arbor, Michigan, September 27-29, 1982.

  1983cited by this paper
• The design of orally active iron chelators for the treatment of thalassaemia.

  1982cited by this paper
• Hepatocyte iron kinetics in the rat explored with an iron chelator

  1982cited by this paper
• A rapid assay for evaluation of iron-chelating agents in rats.

  1981cited by this paper
• Storage iron kinetics. 3. Study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells.

  1973cited by this paper
• Methods for the Production of Clinically Effective Intermediate and High‐Purity Factor‐VIII Concentrates

  1971cited by this paper
• Studies on intermediary iron metabolism. V. The measurement of non-haemoglobin tissue iron.

  1954cited by this paper

• Deferiprone and Iron–Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects

  2023cites this paper
• Combined administration of membrane-permeable and impermeable iron-chelating drugs attenuates ischemia/reperfusion-induced hepatic injury.

  2022cites this paper
• The Role of Deferiprone in Iron Chelation.

  2018cites this paper
• Pre-treatment of rats with ad-hepcidin prevents iron-induced oxidative stress in the brain.

  2016cites this paper
• Advances in iron chelation: an update

  2011cites this paper
• nonoverloaded mice 3-hydroxypyridin-4- one iron chelators in overloaded and Comparison of the subacute toxicity and efficacy of

  2011cites this paper
• chelators in mice (see comments) Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron

  2011cites this paper
• Nephrology Dialysis Transplantation Aluminium toxicity : its relationship with bone and iron metabolism

  2005cites this paper
• The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.

  2004cites this paper
• 5.4 – Iron

  2003cites this paper
• New analgesic and antiinflammatory agents 4(1H)-pyridinone derivatives.

  2002cites this paper
• Clinical use, therapeutic aspects and future potential of deferiprone in thalassemia and other conditions of iron and other metal toxicity.

  2001cites this paper
• The hexadentate hydroxypyridinonate TREN-(Me-3,2-HOPO) is a more orally active iron chelator than its bidentate analogue.

  2000cites this paper
• In Vitro and In Situ Permeability of a 'Second Generation' Hydroxypyridinone Oral Iron Chelator: Correlation with Physico-Chemical Properties and Oral Activity

  1999cites this paper
• Prevalence of yersinia plasmid-encoded outer protein (Yop) class-specific antibodies in multitransfused Greek patients with thalassemic syndromes.

  1999cites this paper
• Acute iron intoxication: the efficacy of deferiprone and sodium biocarbonate in the prevention of iron absorption from the digestive tract.

  1999cites this paper
• The 3-hydroxypyridin-4-ones more effectively chelate aluminum in a rabbit model of aluminum intoxication than does desferrioxamine.

  1996cites this paper
• Aluminium toxicity: its relationship with bone and iron metabolism.

  1996cites this paper
• Effect of iron overload on the metabolism and urinary recovery of 3-hydroxypyridin-4-one chelating agents in the rat.

  1995cites this paper
• Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.

  1995cites this paper
• New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.

  1995cites this paper
• Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.

  1995cites this paper
• CRITICAL REVIEW OF STANDARD AND NEW METHODS OF ASSESSING COMPLIANCE WITH CHELATION THERAPY IN THALASSEMIC PATIENTS

  1995cites this paper
• Interaction of polymorphonuclear leukocytes with Yersinia enterocolitica: role of the Yersinia virulence plasmid and modulation by the iron-chelator desferrioxamine B.

  1994cites this paper
• Synthesis and iron(III) binding properties of 3-hydroxypyrid-4-ones derived from kojic acid.

  1994cites this paper
• Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1).

  1994cites this paper
• Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94

  1994cites this paper
• Oral iron-chelating therapy: the L1 experience.

  1994cites this paper
• 10 Oral iron-chelating therapy: the L1 experience

  1994cites this paper
• Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases

  1993cites this paper
• Iron (III)-chelating resins. 3. Synthesis, iron (III)-chelating properties, and in vitro antibacterial activity of compounds containing 3-hydroxy-2-methyl-4(1H)-pyridinone ligands.

  1993cites this paper
• Iron(III) chelating resins II. 3-Hydroxy-4(1H)-pyridinones-sepharose gels.

  1992cites this paper
• Stabilities of 1,2-dimethyl-3-hydroxy-4-pyridinone chelates of divalent and trivalent metal ions

  1992cites this paper
• Iron(III) chelating resins--I. Preparation and properties of Sepharose-desferrioxamine gels.

  1992cites this paper
• Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.

  1992cites this paper
• Complexation of iron with the orally active decorporation drug L1 (3-hydroxy-1,2-dimethyl-4-pyridinone).

  1992cites this paper
• The chelation of nonheme iron within sickle erythrocytes by the hydroxypyridinone chelator CP094.

  1992cites this paper
• Development of iron-chelating agents for clinical use.

  1992cites this paper
• ASSESSMENT OF ORAL 1,2‐DIMETHYL–3‐HYDROXYPYRID–4–ONE (L1) IN DIFFERENT FERRIKINETIC MODELS IN ANIMALS AND HUMANS

  1991cites this paper
• Comparative iron mobilizing actions of deferoxamine, 1,2-dimethyl-3-hydroxypyrid-4-one, and pyridoxal isonicotinoyl hydrazone in iron hydroxamate-loaded mice.

  1991cites this paper
• ASSESSMENT OF ORAL 1,2‐DIMETHYL–3‐HYDROXYPYRID–4–ONE (L1) IN DIFFERENT FERRIKINETIC MODELS IN ANIMALS AND HUMANS

  1991cites this paper
• Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice.

  1991cites this paper
• NUCLEAR HYPERSEGMENTATION IN MYELOMA CELLS

  1991cites this paper
• Insights into the complex aluminium and iron relationship.

  1991cites this paper
• Studies of an oral iron chelator: 1,2 ‐dimethyl‐ 3 ‐hydroxy‐pyrid‐4‐one I. IRON EXCRETION IN RATS: DEVELOPMENT OF A NEW RAPID MICROWAVE METHOD FOR IRON ANALYSIS IN FAECES

  1990cites this paper
• Effect of novel 1‐alkyl‐3‐hydroxy‐2‐methylpyrid‐4‐one chelators on uptake and release of iron from macrophages

  1990cites this paper
• L1 (1,2‐dimethyl‐3‐hydroxypyrid‐4‐one) for oral iron chelation in patients with beta‐thalassaemia major

  1990cites this paper
• Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice.

  1990cites this paper
• The development of iron chelating drugs.

  1989cites this paper
• Animal toxicology of iron chelator L1.

  1989cites this paper
• Oral iron chelators: Prospects for future development

  1989cites this paper
• 2 The development of iron chelating drugs

  1989cites this paper
• Synthesis and X-ray crystal structure of tris(1,2-dimethyl-3-hydroxypyrid-4-onato)iron(III)

  1988cites this paper
• Care of physically handicapped young adults

  1988cites this paper
• The effect of synthetic iron chelators on bacterial growth in human serum.

  1988cites this paper
• Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant.

  1988cites this paper
• Synthetic methods and in vitro iron binding studies of the novel 1-alkyl-2-ethyl-3-hydroxypyrid-4-one iron chelators

  1988cites this paper
• Selection of hydroxypyridin-4-ones for the treatment of iron overload using in vitro and in vivo models.

  1988cites this paper
• Iron chelating drugs

  1988cites this paper